Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

David A. Sallman, Daniel J. DeAngelo, Naveen Pemmaraju, Shira Dinner, Saar Gill, Rebecca L. Olin, Eunice S. Wang, Marina Konopleva, Eileen Stark, Ana Korngold, Asifa Haider, Kate Backhouse, Carolyn Figliola, Daniel J. Lee, Mark G. Frattini, Carrie Brownstein, Gail J. Roboz

Blood (2022) 140 (Supplement 1): 2371–2373.

https://doi.org/10.1182/blood-2022-169928

Published: 2022

Journal Articles

Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, Gail J. Roboz, Marina Konopleva, Hongtao Liu, Gary J. Schiller, Elias J. Jabbour, Deborah Whitfield, Asifa Haider, Oleg Zernovak, Mark G. Frattini, Carrie Brownstein, Richard A. Larson

Blood (2021) 138 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2021-150779

Published: 2021

Journal Articles

Pre-Clinical Development of a Highly Efficient TALEN ® -Based Correction of the β-Globin Gene in Patient-Derived Hematopoietic Stem and Progenitor Cells (HSPCs) to Treat Sickle Cell Disease

Blood (2021) 138 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2021-153549

Published: 2021

Journal Articles

Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Gail J. Roboz, MD, Daniel J. DeAngelo, MD PhD, David A. Sallman, MD, Monica L. Guzman, PhD, Pinkal Desai, MDMPH, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Francisco Javier Esteva, MD PhD, Andrew Garton, Kate Backhouse, Roman Galetto, PhD, Carrie Brownstein, MD, Naveen Pemmaraju, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138984

Published: 2020

Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2207.

https://doi.org/10.1182/blood-2019-129386

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, MD PhD, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Jun Zhang, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 668.

https://doi.org/10.1182/blood-2019-129288

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Ruben A Mesa, MD, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Carrie Brownstein, MD, Shien Guo, PhD, Xiaomei Ye, MS, Claire N Harrison, Professor

Blood (2019) 134 (Supplement_1): 704.

https://doi.org/10.1182/blood-2019-129020

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Juan Shen, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 4165.

https://doi.org/10.1182/blood-2019-130069

Published: 2019

Journal Articles

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Rajat Bannerji, MD PhD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jon Arnason, MD, Susan M. O'Brien, MD, John N. Allan, MD, Julio C. Chavez, MD, Jeffrey A. Barnes, MD PhD, Robin Joyce, MD, Stephen Ansell, MD PhD, Max S Topp, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ana Kostic, PhD, Anne Paccaly, PharmD, PhD, Bo Gao, PhD, Pamela A. Trail, PhD, Israel Lowy, MD PhD, Carrie Brownstein, MD

Blood (2016) 128 (22): 621.

https://doi.org/10.1182/blood.V128.22.621.621

Published: 2016

Journal Articles

Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages

Carrie Brownstein, Arunkumar B. Deora, Andrew T. Jacovina, Rebecca Weintraub, Menard Gertler, K. M. Faisal Khan, Domenick J. Falcone, Katherine A. Hajjar

Blood (2004) 103 (1): 317–324.

https://doi.org/10.1182/blood-2003-04-1304

Published: 2004

NARROW

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Pre-Clinical Development of a Highly Efficient TALEN ® -Based Correction of the β-Globin Gene in Patient-Derived Hematopoietic Stem and Progenitor Cells (HSPCs) to Treat Sickle Cell Disease

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only